However, studies have also shown that integrins can control tumor stemness without interacting with the ECM, and that this adhesion-independent activity activates pathways that are distinct from common signaling cascades and cytoskeletal connections [20]: this presents a considerable obstacle to the creation of therapeutic medicines that target the ligand or receptor of ITGB1. The gene discussed is ITGB1; the disease is neoplasm.